Lipopolysaccharide-induced increases in cytokines in discrete mouse brain regions are detectable using Luminex xMAP technology.
Methods to determine cytokine protein content in samples of interest, such as enzyme-linked immunosorbent assay (ELISA), are often labor-intensive and costly. Furthermore, because ELISA requires relatively large sample volumes and protein concentrations, it is difficult using this technique to determine protein content for multiple cytokines from individual samples. Recently, Luminex has developed an open source hardware platform combining flow cytometry- and bead-based antibody capture that is capable of detecting multiple analytes from a single sample. In the present study we employed the Luminex 200 platform to determine the cytokine protein content in discrete brain regions of C57BL/6J mice. In spike-and-recovery experiments, known concentrations of murine recombinant interleukin (IL)-1beta, IL-6, and tumor necrosis factor (TNF)alpha were added either singly or as a mixture of all three to whole brain homogenates containing known quantities of total protein. Spiked samples were assayed for either a single cytokine or for multiple cytokines using 1-plex or 3-plex assay kits, respectively. In whole mouse brain homogenate we recovered between 81% and 103% of the recombinant cytokines. We then injected C57BL/6J mice intraperitoneally with bacterial lipopolysaccharide (LPS) and sacrificed them 4h later. We detected in samples taken from LPS-stimulated mice 4- to 870-fold increases in serum or spleen cytokine protein, and 1.5- to 16-fold increases in cytokine protein in discrete brain regions, relative to protein content in samples obtained from vehicle-treated animals. These results indicate that multiple cytokines may be reliably assayed from discrete regions of mouse brain using a single sample.
Datta
Subhash C
SC
Department of Anesthesiology, University of Michigan, Ann Arbor, MI 48109, USA.
Opp
Mark R
MR
D000818:Animals; D001921:Brain / Q000033:anatomy & histology / Q000187:drug effects / Q000378:metabolism; D016207:Cytokines / Q000378:metabolism*; D005786:Gene Expression Regulation / Q000187:drug effects*; D053583:Interleukin-1beta / Q000378:metabolism; D015850:Interleukin-6 / Q000378:metabolism; D008163:Luminescent Measurements / Q000295:instrumentation* / Q000379:methods; D008297:Male; D051379:Mice; D008810:Mice, Inbred C57BL; D011134:Polysaccharides / Q000494:pharmacology*; D014409:Tumor Necrosis Factor-alpha / Q000378:metabolism
D016207:Cytokines; D053583:Interleukin-1beta; D015850:Interleukin-6; D011134:Polysaccharides; D014409:Tumor Necrosis Factor-alpha
J Appl Physiol (1985). 2002 Jun;92(6):2648-55
12015385
Physiol Rev. 1999 Jan;79(1):1-71
9922367
J Neurosci Methods. 2004 Jun 15;136(1):87-98
15126049
Cytometry B Clin Cytom. 2004 Sep;61(1):35-9
15351980
Am J Clin Pathol. 2002 Sep;118(3):346-53
12219776
J Endocrinol Invest. 2001 Nov;24(10):786-95
11765048
Clin Diagn Lab Immunol. 2003 Jan;10(1):133-9
12522051
J Neurotrauma. 2007 Nov;24(11):1707-17
18001201
Neuroimmunomodulation. 1998 May-Aug;5(3-4):160-5
9730681
Brain Behav Immun. 2004 May;18(3):274-80
15050654
J Immunol. 1991 Apr 1;146(7):2316-23
2005401
Glia. 2007 Apr 1;55(5):453-62
17203472
Neurol Clin. 2006 Aug;24(3):441-60
16877117
Sleep Med Rev. 2005 Oct;9(5):355-64
16102986
Cytokine. 2005 Dec 7;32(5):194-8
16257531
J Immunol Methods. 2005 Jul;302(1-2):172-81
16023134
Cytokine. 2000 Aug;12(8):1205-10
10930297
J Neuroimmunol. 2007 Sep;189(1-2):41-9
17655939
Physiol Res. 2003;52(5):593-8
14535835
Clin Chem. 2005 Jul;51(7):1102-9
15976097
J Inflamm (Lond). 2006 Nov 29;3:15
17134510
Am J Pathol. 1991 Feb;138(2):395-402
1992764
Mol Med. 1997 Dec;3(12):864-75
9440119
Clin Diagn Lab Immunol. 2002 Jul;9(4):872-6
12093688